PAM50 intrinsic subtype and risk of recurrence score (ROR) for the prediction of endocrine (ET) sensitivity and pathologic response to chemotherapy in postmenopausal women with clinical stage II/III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC) in the ALTERNATE trial (Alliance A011106)
- Citation:
- Cancer Res vol 82 (4_supplement) abst PD9-03.
- Meeting Instance:
- SABCS 2021
- Year:
- 2022
- Type:
- Abstract
- Sub type:
- Poster/Oral
- Funding:
- NCTN
- Endpoint:
- Secondary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- ppub
- Note:
- Methodological:
- No
- Biospecimen:
- Yes
- SDC:
- Yes
- Parents:
- None
- Children:
- 3910